WHWK
Whitehawk Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.15
+1.45%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$3.22
From 52W high−38.33%
Volume318066.00
Market cap$179.29M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$3.22
From 52W high
−38.33%
Volume
318066.00
Market cap
$179.29M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.1x
P/E (TTM)
—
RSI (14)
40.2
MomentumView details →
1D Return
+1.45%
YTD Return
+29.34%
SummaryUpdated Jun 1, 2026
Whitehawk Therapeutics Inc (NASDAQ:WHWK) is a clinical-stage biopharmaceutical company that underwent a significant strategic transformation in 2024. Originally founded as Aadi Biosciences and going public in 2017, the company initially focused on developing precision therapies for genetically-defined cancers, particularly through its drug FYARRO for rare sarcomas. In late 2024, the company rebranded to Whitehawk Therapeutics and pivoted its strategy to focus on developing advanced antibody-drug conjugates (ADCs) for cancer treatment, while divesting its original FYARRO asset to Kaken Pharmaceuticals.
Similar companies
Latest newsMore news →
Whitehawk Therapeutics presented two real-world analyses at WCLC 2026 in Seoul supporting PTK7 as a durable ADC target in pretreated EGFR wild-type NSCLC, reinforcing the rationale for its next-generation PTK7-directed ADC HWK-007 in Phase 1 development.52d agoWhitehawk Therapeutics appointed Vijay Iyengar as a Class III director effective September 9, 2026, with an initial stock option award for 76,080 shares.55d ago